Visit Us @
Synergy Centre TU Dublin, Tallaght, D24A386
Mail Us @
info@codlad.com
Call Us @
+353 851890752

Archive for May 23, 2023

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

May 23, 2023

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use…

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder FDA
FDA Roundup: May 23, 2023

May 23, 2023

FDA Roundup: May 23, 2023

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans…

FDA Roundup: May 23, 2023 FDA

Latest Posts

FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
March 20, 2026
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
March 19, 2026
FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development
FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development
March 18, 2026